13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001802528
Total reported value
$1.5B
$1.5B
13 檔
55.5%
As reported in its official Q4 2025 Form 13F filing, Fairmount Funds Management LLC's tracked investment portfolio stood at $1.5B with 13 total positions.
In Q4 2025, Fairmount Funds Management LLC adopted a defensive or profit-taking posture, trimming 2 positions and completely liquidating 4 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | COGT | Cogent Biosciences Inc | Stock-Other | 24.34% | -1.22% | — | |
| 2 | APGE | Apogee Therapeutics Inc | Stock-Other | 11.77% | +0.80% | — | |
| 3 | SYRE | Spyre Therapeutics Inc | Stock-Other | 10.02% | -14.64% | EXIT | |
| 4 | VRDN | Viridian Therapeutics Inc | Stock-Other | 9.27% | +0.65% | +13.14% | |
| 5 | ORKA | Oruka Therapeutics Inc | Stock-Other | 8.55% | +10.18% | — | |
| 6 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 6.70% | +0.97% | -35.38% | |
| 7 | ZBIO | Zenas Biopharma Inc | Stock-Other | 6.11% | +0.63% | +16.71% | |
| 8 | NUVL | Nuvalent Inc-a | Stock-Other | 5.57% | — | — | |
| 9 | JBIO | Jade Biosciences Inc | Stock-Other | 5.35% | +2.07% | +41.40% | |
| 10 | ELVN | Enliven Therapeutics Inc | Stock-Other | 4.35% | +0.97% | — | |
| 11 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 4.14% | — | -25.56% | |
| 12 | ✓ | Crescent Biopharma Inc. | Stock-Other | 2.48% | -0.38% | +97.99% | |
| 13 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 1.35% | +0.11% | +40.82% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | COGT | Cogent Biosciences Inc | +12.7% | — | Unchanged |
| 2 | APGE | Apogee Therapeutics Inc | +4.5% | — | Unchanged |
| 3 | SYRE | Spyre Therapeutics Inc | +4% | — | Unchanged |
| 4 | JBIO | Jade Biosciences Inc | +2.9% | +41.40% | Add |
| 5 | VRDN | Viridian Therapeutics Inc | +2.6% | +13.14% | Add |
| 6 | ZBIO | Zenas Biopharma Inc | +2.3% | +16.71% | Add |
| 7 | ORKA | Oruka Therapeutics Inc | +2.1% | — | Unchanged |
| 8 | ✓ | Crescent Biopharma Inc. | +1% | +97.99% | Add |
| 9 | IKT | Inhibikase Therapeutics Inc | +0.5% | +40.82% | Add |
| 10 | NUVL | Nuvalent Inc-a | -0.1% | — | Unchanged |
| 11 | KNSA | Kiniksa Pharmaceuticals International, plc | -2.1% | -25.56% | Trim |
| 12 | ELVN | Enliven Therapeutics Inc | -2.5% | — | Unchanged |
| 13 | DNTH | Dianthus Therapeutics Inc | -5% | -35.38% | Trim |
| 14 | AXSM | Axsome Therapeutics Inc | — | EXIT | Sold out |
| 15 | SRRK | Scholar Rock Holding CORP | — | EXIT | Sold out |
| 16 | ABVX | Abivax Sa-adr | — | EXIT | Sold out |
| 17 | CATBUSD | Astria Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Fairmount Funds Management LLC reported a total U.S. public equity portfolio value of $1.5B across 13 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including COGT, APGE, SYRE) accounted for 55.5% of total reported equity market value during Q4 2025.
Top Position Liquidated / Trimmed
AXSM
前期市值: $99.0M
During Q4 2025, Fairmount Funds Management LLC's top holdings by market value included COGT (24.3%)、APGE (11.8%)、SYRE (10.0%). The largest single position, COGT, represented 24.3% of total portfolio value.
In Q4 2025, Fairmount Funds Management LLC made 11 total portfolio adjustments, initiating 0 new buys, adding to 5 positions, trimming 2 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.